Next Article in Journal
Multigene Family of Pore-Forming Toxins from Sea Anemone Heteractis crispa
Next Article in Special Issue
Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids: Dichotomy between Experimental and Clinical Studies
Previous Article in Journal
Anti-Aging Effect of Chitosan Oligosaccharide on d-Galactose-Induced Subacute Aging in Mice
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle
Mar. Drugs 2018, 16(6), 182; https://doi.org/10.3390/md16060182

Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats

1
School of Health and Wellbeing, Faculty of Health, Engineering and Sciences, University of Southern Queensland, Toowoomba QLD 4350, Australia
2
Functional Foods Research Group, Institute for Agriculture and the Environment, University of Southern Queensland, Toowoomba QLD 4350, Australia
3
Department of Radiation Oncology, Calvary Mater Newcastle, Waratah NSW 2298, Australia
4
Genesis Cancer Care, Lake Macquarie Private Hospital, Gateshead NSW 2290, Australia
Current Address: School of Biotechnology and Bioinformatics, DY Patil University, Nerul, Navi Mumbai, Maharashtra 400706, India.
*
Author to whom correspondence should be addressed.
Received: 22 April 2018 / Revised: 12 May 2018 / Accepted: 22 May 2018 / Published: 24 May 2018
(This article belongs to the Special Issue Marine Natural Products for Cardiovascular Disease)
Full-Text   |   PDF [5545 KB, uploaded 24 May 2018]   |  

Abstract

Inducing testosterone deficiency, as the standard treatment of prostate cancer, may cause metabolic disorders including insulin resistance, dyslipidemia, central obesity, cardiovascular diseases, and type 2 diabetes. This study measured responses to testosterone deficiency in high-carbohydrate, high-fat (H) diet-fed rats. We then tested whether eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) ethyl esters (Omacor) reversed these metabolic changes. Male Wistar rats (8–9 weeks old) were divided into eight groups with four groups fed corn starch and four groups fed H diet. For each diet, one group received diet only; one group was orchidectomized; one group was given leuprolide (gonadotrophin-releasing hormone agonist, 2 mg/kg every 4th week); and the last group was treated with leuprolide and their diet was supplemented with 3% Omacor for the last eight weeks. The protocol was for 16 weeks. Leuprolide worsened metabolic syndrome symptoms and cardiovascular function, and orchidectomy produced greater responses. In H fed leuprolide-treated rats, Omacor decreased systolic blood pressure and left ventricular diastolic stiffness, reduced infiltration of inflammatory cells and collagen deposition in the heart, and reduced lipid accumulation and inflammatory cell infiltration without improving liver damage. These results suggest that Omacor has potential to attenuate metabolic complications in prostate cancer patients with induced testosterone deprivation. View Full-Text
Keywords: testosterone; obesity; metabolic syndrome; leuprolide; EPA/DHA ethyl esters testosterone; obesity; metabolic syndrome; leuprolide; EPA/DHA ethyl esters
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Bhandarkar, N.S.; Kumar, S.A.; Martin, J.; Brown, L.; Panchal, S.K. Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats. Mar. Drugs 2018, 16, 182.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top